浙江医学2018，Vol.40Issue(3)：235-239,5.DOI:10.12056/j.issn.1006-2785.2018.40.3.2016-1569
绝经前高危复发乳腺癌辅助内分泌治疗的最佳方案研究
Optimal adjuvant endocrine therapy for premenopausal high-risk recurrence breast cancer
摘要
Abstract
Objective To assess regimes of adjuvant endocrine therapy for premenopausal women with high-risk recurrence breast cancer.Methods One hundred and fifty two premenopausal women with high-risk recurrence breast cancer were enrolled.Patients were randomly divided into three groups with 50 cases each:Group T (tamoxifen alone),group G+T (goserelin + tamoxifen) and group G+A (goserelin+anastrozole).The patients were followed-up and the 3-year disease-free survival(DFS) rate and 4-year overall survival(OS) rate were observed and compared among three groups.Results The median follow-up was 49 months,the 3-year DFS rate in G+A group was 90.00％,which was significantly higher than group T (74.00％) (x2=5.986,P＜0.05);the 4-year OS rate in groups G+A,G+T and T were 95.70％,92.90％ and 89.50％,respectively (P ＞0.05).The 3-year DFS rate in Her-2 positive patients of group T was significantly lower than that in Her-2 negative patients.For Her-2 positive patients the 3-year DFS rate in group G+A was significantly higher than that in groups G +T and T.The 3-year DFS rate in G +A group was significantly higher than that in group T for patients aged ＜40 years or with ＞10 metastatic lymph nodes.The side-effects were slightly different among the 3 groups while all tolerable.Conclusion In premenopausal women with high-risk recurrence breast cancer,adjuvant endocrine therapy with ovarian suppression combined aromatase inhibitors can significantly reduce the risk of recurrence,compared to TAM alone.关键词
乳腺癌/绝经前/内分泌治疗/卵巢功能抑制Key words
Breast cancer/Premenopause/Endocrine therapy/Ovarian function suppression引用本文复制引用
封伟亮,陈道宝,陈波,乔恩奇,俞星飞,杨红健..绝经前高危复发乳腺癌辅助内分泌治疗的最佳方案研究[J].浙江医学,2018,40(3):235-239,5.基金项目
浙江省卫生厅科技计划项目(2011RCB010) （2011RCB010）
